Oncology · Medical Literature
[Articles] Switching to camizestrant at ESR1 mutation emergence before disease progression during first-line treatment of hormone receptor-positive advanced breast cancer (SERENA-6): extended analysis of a double-blind, placebo-controlled, randomised, phase 3 trial
Abstract
Switching to camizestrant plus CDK4/6 inhibitor at ESR1 mutation emergence, versus continuing aromatase inhibitor plus CDK4/6 inhibitor, resulted in sustained progression-free survival benefit that translated into a statistically significant improvement in second progression-free survival. These results further support switching endocrine treatment to camizestrant from aromatase inhibitor upon detection of ESR1 mutation, with continuation of any of the globally approved CDK4/6 inhibitor, to extend first-line treatment benefit.
Clinical relevance
In patients with hormone receptor-positive, HER2-negative advanced breast cancer receiving first-line aromatase inhibitor (AI) plus CDK4/6 inhibitor therapy, does switching to camizestrant (a next-generation oral SERD) upon ctDNA detection of an emergent ESR1 mutation—before radiographic progression—improve progression-free survival (PFS), second progression-free survival (PFS2), and other outcomes compared with continuing AI plus CDK4/6 inhibitor? __SNAPSHOT__ {"studyDesign":"Phase 3 randomized, double-blind, placebo-controlled trial (SERENA-6); this publication represents an extended analysis with updated PFS and final PFS2 data with longer follow-up, plus exploratory ctDNA dynamics analyses. Primary results were previously published in the New England Journal of Medicine (2025).","setting":"Global, multi-center registrational trial; described as the first global registrational study to use prospective ctDNA monitoring to direct therapy change in hormone receptor-positive advanced breast cancer","sampleSize":"n=315 randomized (camizestrant arm: n=157; AI continuation arm: n=158); screened from a total of 3,256 patients tested for ESR1 mutations","population":"Adult patients with histologically confirmed HR-positive, HER2-negative locally advanced or metastatic breast cancer who had received at least 6 months of first-line AI plus CDK4/6 inhibitor (palbociclib, ribociclib, or abemaciclib) and were found to have an emergent ESR1 mutation in ctDNA without concurrent radiological progression","intervention":"Switch to camizestrant 75 mg orally once daily plus continued CDK4/6 inhibitor (at same dose as surveillance phase) plus placebo in place of AI","comparator":"Continuation of AI (anastrozole 1 mg or letrozole 2.5 mg orally once daily) plus CDK4/6 inhibitor (same dose) plus placebo in place of camizestrant","primaryOutcome":"Investigator-assessed progression-free survival (PFS) per RECIST 1.1; key secondary outcome included PFS2 (time from randomization to second disease progression or death)","followUp":"Updated PFS analysis: median follow-up 23.5 months; interim PFS analysis (previously published): median follow-up 12.6 months","fundingSource":"Industry (AstraZeneca)"}
Key findings
At the previously reported interim analysis (median follow-up 12.6 months), median PFS was 16.0 months (95% CI 12.7–18.2) in the camizestrant arm versus 9.2 months (95% CI 7.2–9.5) in the AI-continuation arm (HR 0.44; 95% CI 0.31–0.60; P<0.0001), representing an absolute difference of approximately 6.8 months. In the updated PFS analysis at a median follow-up of 23.5 months, median PFS was 16.8 months (95% CI 14.7–19.4) versus 9.2 months (95% CI 7.2–9.7) for camizestrant versus AI continuation, respectively (HR 0.45; 95% CI 0.34–0.59; nominal P<0.00001), corresponding to a 55% reduction in the risk of progression or death. PFS benefit was consistent across pre-specified subgroups, including PIK3CA co-mutation (HR 0.41; 95% CI 0.26–0.64), TP53 co-mutation (HR 0.52; 95% CI 0.31–0.88), single ESR1 mutation (HR 0.46; 95% CI 0.34–0.62), and multiple ESR1 mutations (HR 0.48; 95% CI 0.25–0.88). This extended analysis demonstrated that the PFS benefit translated into a statistically significant improvement in PFS2; the absolute median PFS2 gain was approximately 6.6 months (HR 0.63; exact confidence intervals and p-value for PFS2 not reported in the available abstract). Chemotherapy/ADC-free survival was 22.6 versus 18.7 months (HR 0.64; exact confidence intervals not reported in available abstract), suggesting delayed need for cytotoxic or ADC therapies. Exploratory ctDNA analyses showed total ctDNA clearance in 51.0% of patients in the camizestrant arm versus 1.9% in the AI-continuation arm; ctDNA clearance correlated with improved overall survival across both arms (HR 0.39; confidence intervals not reported in available abstract—this is an exploratory, hypothesis-generating finding). Patient-reported outcomes (previously published) showed delayed time to deterioration in global health status/quality of life (HR 0.54; 95% CI 0.34–0.84) and in pain (median 16.6 vs 6.5 months; HR 0.57; 95% CI 0.37–0.86) favoring camizestrant. Regarding safety, grade ≥3 adverse events occurred in 60.0% (camizestrant arm) versus 45.8% (AI arm), driven primarily by CDK4/6 inhibitor-associated hematologic toxicities. Photopsia was the most common non-hematologic adverse event, occurring in 20.0% versus 7.7%; events were predominantly low-grade with no associated structural ocular changes. The discontinuation rate due to adverse events was low (1.3% in the camizestrant arm). Overall survival data are not yet mature. NNT for PFS benefit: not calculable from available abstract data.
Practice implications
SERENA-6 establishes that proactive, ctDNA-guided switching from an AI to camizestrant—upon detection of an emergent ESR1 mutation before clinical or radiographic progression—significantly prolongs first-line PFS and, in this extended analysis, also improves PFS2, suggesting that the early treatment benefit is durable and not merely displaced to a later time point. This is clinically meaningful because ESR1 mutations are the most common mechanism of acquired resistance to AI-based first-line therapy, emerging in approximately 30–40% of patients, and ctDNA monitoring can detect them 3–6 months before radiographic progression. The findings apply to patients with HR-positive, HER2-negative advanced breast cancer receiving first-line AI plus any of three approved CDK4/6 inhibitors, in whom serial ctDNA ESR1 surveillance is feasible. Patients who received prior endocrine therapy in the early-stage setting, those unable to undergo serial ctDNA monitoring, and those with de novo ESR1 mutations or non-AI first-line regimens were not adequately represented and may not be generalizable. IMPORTANT CAVEAT — REGULATORY UNCERTAINTY: Despite the statistically significant and seemingly clinically meaningful PFS and PFS2 results, the FDA's Oncologic Drugs Advisory Committee (ODAC) voted 6–3 in April 2026 that the data did not demonstrate clinically meaningful benefit, partly because the FDA determined that PFS2 may not be an acceptable regulatory endpoint when the treatment switch in the experimental arm is initiated at the time of molecular (rather than radiographic) detection. The FDA's regulatory decision was deferred to allow review of additional data. Overall survival data remain immature and are not reported. The absence of crossover to camizestrant at radiographic progression in the control arm limits definitive assessment of whether early molecular switching improves OS versus waiting for clinical progression. Real-world implementation requires access to validated, serial ctDNA ESR1 assays and infrastructure for routine monitoring. NOTE: This summary is based primarily on the abstract of the July 2026 Lancet Oncology extended analysis plus data presented at ASCO 2026 and previously published in NEJM (2025); full manuscript data may contain additional findings not captured here. __LIMITATIONS__ Overall survival data are immature; no OS benefit has been demonstrated to date, and it is unknown whether earlier switching improves OS or merely displaces progression events.,ODAC voted 6–3 against clinically meaningful benefit, citing concerns that PFS2 may not be appropriate as a registrational endpoint in this design, where the experimental arm switches at molecular detection rather than clinical progression.,The absence of crossover to camizestrant at radiographic progression in the control arm limits differentiation between 'early switch' benefit and 'total exposure' benefit.,The trial enrolled only 315 patients from a screened pool of 3,256, raising selection and feasibility concerns; the ~10% yield of ESR1-mutation-positive, progression-free patients limits applicability in routine practice.,Industry sponsorship (AstraZeneca) by the manufacturer of camizestrant introduces potential for bias in study design, analysis, and reporting.,Exploratory ctDNA clearance-to-OS correlation is hypothesis-generating only and should not be used to guide clinical decisions.,The study was double-blind but the ctDNA-guided design required serial blood draws and centralized assay infrastructure, which may not be available in all clinical settings, limiting generalizability.,Subgroup analyses (PIK3CA, TP53, ESR1 mutation count) were not pre-specified as primary and are subject to multiplicity concerns.,The photopsia signal (20.0% vs 7.7%), although predominantly low-grade, warrants ongoing ophthalmologic surveillance in clinical practice.,Whether the PFS2 improvement reflects a true disease-modifying effect or is an artifact of the trial's ctDNA-based design (i.e., patients in the camizestrant arm had a longer first-line treatment period before any 'second-line' clock started) cannot be fully excluded without OS data. __BOTTOM_LINE_CATEGORY__ potentially_practice_informing __BOTTOM_LINE__ SERENA-6 demonstrates that ctDNA-guided, pre-progression switching from an AI to camizestrant plus a CDK4/6 inhibitor at ESR1 mutation emergence significantly prolongs PFS (median 16.8 vs 9.2 months; HR 0.45) and, in this extended analysis, also achieves statistically significant improvement in PFS2 (absolute gain ~6.6 months; HR 0.63). However, OS benefit remains unproven, and the FDA's advisory committee voted against clinical meaningfulness—pending final regulatory review—meaning camizestrant cannot yet be considered a confirmed standard of care for this indication, though the totality of evidence strongly informs practice for clinicians who have access to validated serial ctDNA surveillance.